GT Biopharma, Inc.
GTBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.00 | 0.60 | 0.65 |
| FCF Yield | -223.03% | -85.90% | -1.80% | -0.61% |
| EV / EBITDA | -0.14 | 1.55 | -40.13 | -44.67 |
| Quality | ||||
| ROIC | 860.12% | -180.20% | -178.51% | -262.13% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | 1.17 | 0.73 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -45.77% | 41.83% | 2.49% | -114.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | -0.17 | 0.26 | 0.16 |
| Interest Coverage | 0.00 | -63.74 | -2,657.13 | -80.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |